Brought to you by 
Sapphire Therapeutics licenses Novo Nordisk ghrelin compound
02 Nov 2006
Executive Summary
Sapphire Therapeutics (formerly Rejuvenon Corp.; in-licenses development candidates for cancer and metabolic disorders) has licensed from Novo Nordisk worldwide exclusive rights to a small-molecule compound related to the ghrelin pathway, which it will first develop for postoperative ileus (POI), or constipation following surgery.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sapphire Therapeutics licenses Novo Nordisk ghrelin compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice